Phase II study of mitozolomide (M & B 39,565) in head and neck cancer
- 11 Downloads
Nineteen patients with advanced head and neck cancer were given mitozolomide (MTZ), i.v. infusion, every 6 weeks. The starting dose was 100 mg m−2. When it was well tolerated, dose escalation was performed up to 110–115 mg m−2. The limiting toxicity was thrombocytopenia, often mild, but occasionally severe, with hemorrhage and the need for platelet transfusions in two patients. The platelet nadir was 85 × 109 1−1 (11–225). No response was observed in 14 evaluable patients. MTZ, according to this schedule and dosage does not show significant activity in human squamous cell head and neck cancer.
Key wordsMitozolomide Head and neck cancer Phase II
Unable to display preview. Download preview PDF.
- 2.Fostad O, Aamdal S, Pihl Aet al: Activity of mitozolomide (NSC 353451) a new imidazotetrazine against xenografts from human melanomas, sarcomas, lung and colon carcinomas.Cancer Res 45, 1778 (1985).Google Scholar
- 3.Horgan C M T, Stevens M F G, Tisdale M J: Preliminary investigation on the mode of action of CCRG 81010 (M and B 39,565).Br J Cancer 48, 132 (1983).Google Scholar
- 5.Slack J A, Newlands E S, Blackledge Get al: Clinical pharmacokinetics of mitozolomide (M & B 39,565, CCRG 81010, NSC 353451) (abstract). AACR Annual Meeting, May 9–12th, 1984, Toronto, Canada.Google Scholar
- 7.Herait P, Rougier Ph, May-Levin F, Fontana X, Hayat M, Armand J P: Mitozolomide phase II study in advanced colorectal and breast cancer (abstract), in5th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, October 22–28, vol. 2, p. 20 (1986).Google Scholar